% Auto-generated by pathway_shifting_simulation.py
\begin{table}[htbp]
\centering
\caption{Systems biology simulation: intra-axial MHS vs.\ tri-axial combination therapy. ODE-based signaling models simulate adaptive pathway shifting under different treatment strategies. Time to resistance is measured as hours until tumor viability recovers above 0.5. Pathway shift magnitude measures compensatory orthogonal axis upregulation. All tri-axial combinations achieve lower final viability and greater resistance prevention.}
\label{tab:simulation}
\small
\begin{tabular}{@{}llcccccc@{}}
\toprule
\textbf{Cancer} & \textbf{Strategy} & \textbf{Targets} & \textbf{Min V} & \textbf{Final V} & \textbf{AUC} & \textbf{TTR (d)} & \textbf{Shift} \\
\midrule
PDAC & Single (KRAS) & 1 & 0.70 & 0.74 & 0.74 & $>$ 200 & 0.40 \\
 & Intra-axial MHS (KRAS+EGFR) & 2 & 0.70 & 0.81 & 0.81 & $>$ 200 & 0.50 \\
 & Tri-axial (KRAS+CDK4+STAT3) & 3 & 0.52 & 0.52 & 0.52 & $>$ 200 & 0.40 \\
\midrule
Melanoma & Single (BRAF) & 1 & 0.63 & 0.63 & 0.64 & $>$ 200 & 0.50 \\
 & Intra-axial MHS (BRAF+MEK) & 2 & 0.52 & 0.61 & 0.61 & $>$ 200 & 0.50 \\
 & Tri-axial (BRAF+CCND1+STAT3) & 3 & 0.45 & 0.45 & 0.46 & $>$ 200 & 0.36 \\
\midrule
NSCLC & Single (EGFR) & 1 & 0.57 & 1.00 & 1.00 & $>$ 200 & 0.40 \\
 & Intra-axial MHS (EGFR+KRAS) & 2 & 0.57 & 0.67 & 0.67 & $>$ 200 & 0.40 \\
 & Tri-axial (KRAS+CCND1+MCL1) & 3 & 0.43 & 0.57 & 0.57 & $>$ 200 & 0.52 \\
\midrule
CRC & Single (KRAS) & 1 & 0.65 & 0.89 & 0.89 & $>$ 200 & 0.55 \\
 & Intra-axial MHS (KRAS+BRAF) & 2 & 0.65 & 0.72 & 0.72 & $>$ 200 & 0.55 \\
 & Tri-axial (KRAS+CCND1+STAT3) & 3 & 0.46 & 0.46 & 0.46 & $>$ 200 & 0.55 \\
\midrule
Breast & Single (CDK4) & 1 & 0.63 & 0.77 & 0.77 & $>$ 200 & 0.43 \\
 & Intra-axial MHS (CDK4+CDK6) & 2 & 0.61 & 0.65 & 0.65 & $>$ 200 & 0.50 \\
 & Tri-axial (CDK4+KRAS+STAT3) & 3 & 0.36 & 0.36 & 0.37 & $>$ 200 & 0.33 \\
\bottomrule
\end{tabular}
\end{table}